Thursday, July 9, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ERNA”

213 pharma patents match "ERNA" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 213
Index total 30,257
Page 1 / 9

Quick answer

This filtered view shows 213 pharmaceutical patents matching "ERNA" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

213 results for “ERNA” · 30,257 patents in full index Clear search

  1. AU 2024384453

    CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted May 21, 2026 · Expires May 16, 2046

    granted
  2. US 12221414

    Quaternary ammonium salt compound, preparation method therefor and use thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  3. US 12215138

    Compositions and methods for internalizing enzymes

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  4. US 12157729

    Solid state forms of Belumosudil and Belumosudil salts

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  5. US 12139528

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  6. US 12128034

    Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

    Iterum Therapeutics International Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  7. US 12109197

    Combinations of β-lactam compounds and probenecid and uses thereof

    Iterum Therapeutics International Limited · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  8. US 12091388

    Solid state forms of Reproxalap

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  9. US 12005139

    Ophthalmic formulations and related methods

    ETERNATEAR, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  10. US 11964047

    Ophthalmic formulations and related methods

    ETERNATEAR, INC. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  11. AU 2022323463

    ANTIMICROBIAL PEPTIDOMIMETICS

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted Feb 29, 2024 · Expires Feb 24, 2044

    granted
  12. US 11879003

    Methods for increasing T-cell function

    Kyverna Therapeutics, Inc. · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted
  13. US 11813359

    Sustained release olanzapine formulations

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  14. US 11773083

    Solid state forms of Belumosudil and Belumosudil salts

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  15. US 11697639

    Quaternary ammonium salt compound, preparation method therefor and use thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Jul 11, 2023 · Expires Jul 6, 2043

    granted
  16. US 11679078

    Ophthalmic formulations and related methods

    ETERNATEAR, INC. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  17. US 11679079

    Ophthalmic formulations and related methods

    ETERNATEAR, INC. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  18. US 11673860

    Crystalline siponimod fumaric acid and polymorphs thereof

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  19. AU 2021319613

    Antimicrobial peptidomimetics

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted Mar 30, 2023 · Expires Mar 25, 2043

    granted
  20. AU 2021323364

    Antimicrobial peptidomimetics

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted Mar 30, 2023 · Expires Mar 25, 2043

    granted
  21. US 11578135

    Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  22. US 11555064

    Treating headache comprising administering an antibody to calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 17, 2023 · Expires Jan 12, 2043

    granted
  23. US 11541177

    Injection spring for aged prefilled syringe and auto injector

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  24. US 11524017

    Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

    Beijing Normal University Hong Kong Baptist University United International College · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted